Baidu
map

Clin Cancer Res: 考比替尼(cobimetinib)+ 维莫非尼(vemurafenib)对比安慰剂+ 维莫非尼(vemurafenib)治疗BRAF V600突变阳性转移性黑色素瘤的疗效和安全性: coBRIM研究5年长期随访结果

2021-06-26 yd2015 MedSci原创

coBRIM研究表明,在维莫非尼(vemurafenib)基础上加用考比替尼(cobimetinib)治疗BRAF V600突变阳性转移性黑色素瘤可获得长期获益,并且毒性可耐受可控。

coBRIM(NCT01689519)是一项多中心、随机、双盲、安慰剂对照的III期临床研究,评估考比替尼(cobimetinib)+ 维莫非尼(vemurafenib)对比安慰剂+ 维莫非尼(vemurafenib)治疗BRAF V600突变阳性转移性黑色素瘤的疗效和安全性。在初步分析中,中位随访7.3个月时,考比替尼(cobimetinib)+ 维莫非尼(vemurafenib)对比安慰剂+ 维莫非尼(vemurafenib)的中位无进展生存期(PFS)为9.9个月vs 6.2个月(HR=0.51;95%CI,0.39-0.68;P<0.001); OS数据尚未成熟。中位随访14.2个月时,更新的PFS分析显示,考比替尼(cobimetinib)+ 维莫非尼(vemurafenib)的中位PFS改善至12.3个月,而安慰剂组为7.2个月(HR=0.58; 95%CI, 0.46 -0.72;P<0.0001)。中位随访18.5个月时,最终的OS分析显示,与安慰剂+ vemurafenib相比,cobimetinib + vemurafenib显著改善了中位OS (22.3个月vs 17.4个月;HR=0.70; 95%CI, 0.55 - 0.90; P = 0.005)。近期,Clin Cancer Res杂志更新了长期随访的结果。

495例患者随机分为cobimetinib + vemurafenib组 (n = 247)或安慰剂+ vemurafenib 组(n = 248)。cobimetinib + vemurafenib组患者的中位随访时间为21.2个月,安慰剂+ vemurafenib组患者的中位随访时间为16.6个月。在cobimetinib + vemurafenib组与安慰剂+ vemurafenib组中,最常见的中断研究原因是死亡(64% vs 67%)和患者主动撤出(8.5% vs 8.1%)。而中断治疗的最常见原因是疾病进展(58% vs. 76%)和不良事件(17% vs. 9%)。

cobimetinib + vemurafenib组患者的中位OS为22.5个月(95% CI, 20.3 28.8),而安慰剂+ vemurafenib组中位OS为17.4个月(95% CI, 15.0 19.8); 5年OS率分别为31%和26%。

               两组治疗的OS

在接受cobimetinib + vemurafenib治疗的患者中,基线LDH水平正常的患者中位OS为38.5个月(95% CI, 28.0个月-未达到),而基线LDH水平升高的患者中位OS为14.8个月(95% CI, 11.3-18.6个月); 5年OS率分别为43%和16%。

             治疗组LDH分层比较OS

在接受cobimetinib + vemurafenib治疗的患者中,获得完全缓解(未达到;95% CI, 41.2-未达到)或部分缓解(26.5个月;95% CI, 19.7-33.4),而无应答者(9.7个月;95% CI, 6.1-12.6), 5年的OS率分别为55%、29%和13%。

            治疗组治疗应答分层比较OS

cobimetinib + vemurafenib组的中位无进展生存期(PFS)为12.6个月(95% CI, 9.5 14.8),而安慰剂+ vemurafenib组为7.2个月(95% CI, 5.6 7.5); 5年无进展生存率分别为14%和10%。

                两组治疗的PFS

在接受cobimetinib + vemurafenib治疗的患者中,LDH水平正常的患者的中位PFS 为15个月( 95% CI, 12.9-22.0),而基线LDH水平升高组的为8.6个月(95% CI, 7.3-10.0)。

              治疗组LDH分层比较PFS

在接受cobimetinib + vemurafenib治疗的患者中,对比无反应者(3.7个月;95% CI, 3.6 3.8),中位PFS在获得完全缓解患者(41.4个月;95% CI, 28.4 66.8)或部分缓解患者(12.9个月;95% CI, 10.6 14.9)中更长。

              治疗组治疗应答分层比较OS

cobimetinib + vemurafenib组的客观缓解率为172/247例(70%),包括完全缓解52例(21%),部分缓解120例(49%)。而安慰剂+ vemurafenib组的客观缓解率为123/248例(50%),包括完全缓解32例(13%),部分缓解91例(37%)。

两组任何级别治疗相关不良事件(AEs)分别为99%和98%。≥3级AEs分别为78%和63%,主要为γ谷氨酰转移酶(GGT)升高(15% vs. 10%),丙氨酸氨基转移酶(ALT)升高(12% vs. 6%),血肌酸磷酸激酶(CPK)升高(12% vs . <1%)。严重AEs发生率分别为42%和29%。两组发生严重AEs≥2%分别为发热(3% vs 1%)、肺炎(2% vs 1%)和脱水(2% vs. 0)。总体来说,安全性跟既往报道的一致。

综上,coBRIM研究表明,在维莫非尼(vemurafenib)基础上加用考比替尼(cobimetinib)治疗BRAF V600突变阳性转移性黑色素瘤可获得长期获益,并且毒性可耐受可控。

原始出处:

Paolo A Ascierto, Brigitte Dreno, James Larkin, et al. 5-Year Outcomes with Cobimetinib Plus Vemurafenib in BRAF V600 Mutation-Positive Advanced Melanoma: Extended Follow-Up of the coBRIM Study. Clin Cancer Res. 2021 Jun 22;clincanres.0809.2021.  doi: 10.1158/1078-0432.CCR-21-0809. Online ahead of print.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1967228, encodeId=0115196e2287d, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue Jul 27 04:31:42 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045529, encodeId=d07f2045529b8, content=<a href='/topic/show?id=ed70e91027a' target=_blank style='color:#2F92EE;'>#维莫非尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79102, encryptionId=ed70e91027a, topicName=维莫非尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Sep 30 10:31:42 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663183, encodeId=7af2166318345, content=<a href='/topic/show?id=76ed183e2ef' target=_blank style='color:#2F92EE;'>#Vemurafenib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18372, encryptionId=76ed183e2ef, topicName=Vemurafenib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c625536559, createdName=ms1292405679162969, createdTime=Wed Aug 25 01:31:42 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818822, encodeId=1eb4181882215, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jan 19 08:31:42 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680734, encodeId=bfe31680e343a, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Tue Sep 14 23:31:42 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896860, encodeId=6350189686060, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 18 08:31:42 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803563, encodeId=3cc818035637e, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Wed Jun 08 11:31:42 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721040, encodeId=15921e21040a3, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Sep 17 19:31:42 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304403, encodeId=45bd1304403d2, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Mon Jun 28 09:31:42 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355030, encodeId=c105135503078, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 28 09:31:42 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1967228, encodeId=0115196e2287d, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue Jul 27 04:31:42 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045529, encodeId=d07f2045529b8, content=<a href='/topic/show?id=ed70e91027a' target=_blank style='color:#2F92EE;'>#维莫非尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79102, encryptionId=ed70e91027a, topicName=维莫非尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Sep 30 10:31:42 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663183, encodeId=7af2166318345, content=<a href='/topic/show?id=76ed183e2ef' target=_blank style='color:#2F92EE;'>#Vemurafenib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18372, encryptionId=76ed183e2ef, topicName=Vemurafenib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c625536559, createdName=ms1292405679162969, createdTime=Wed Aug 25 01:31:42 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818822, encodeId=1eb4181882215, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jan 19 08:31:42 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680734, encodeId=bfe31680e343a, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Tue Sep 14 23:31:42 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896860, encodeId=6350189686060, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 18 08:31:42 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803563, encodeId=3cc818035637e, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Wed Jun 08 11:31:42 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721040, encodeId=15921e21040a3, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Sep 17 19:31:42 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304403, encodeId=45bd1304403d2, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Mon Jun 28 09:31:42 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355030, encodeId=c105135503078, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 28 09:31:42 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1967228, encodeId=0115196e2287d, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue Jul 27 04:31:42 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045529, encodeId=d07f2045529b8, content=<a href='/topic/show?id=ed70e91027a' target=_blank style='color:#2F92EE;'>#维莫非尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79102, encryptionId=ed70e91027a, topicName=维莫非尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Sep 30 10:31:42 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663183, encodeId=7af2166318345, content=<a href='/topic/show?id=76ed183e2ef' target=_blank style='color:#2F92EE;'>#Vemurafenib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18372, encryptionId=76ed183e2ef, topicName=Vemurafenib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c625536559, createdName=ms1292405679162969, createdTime=Wed Aug 25 01:31:42 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818822, encodeId=1eb4181882215, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jan 19 08:31:42 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680734, encodeId=bfe31680e343a, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Tue Sep 14 23:31:42 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896860, encodeId=6350189686060, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 18 08:31:42 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803563, encodeId=3cc818035637e, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Wed Jun 08 11:31:42 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721040, encodeId=15921e21040a3, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Sep 17 19:31:42 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304403, encodeId=45bd1304403d2, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Mon Jun 28 09:31:42 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355030, encodeId=c105135503078, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 28 09:31:42 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1967228, encodeId=0115196e2287d, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue Jul 27 04:31:42 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045529, encodeId=d07f2045529b8, content=<a href='/topic/show?id=ed70e91027a' target=_blank style='color:#2F92EE;'>#维莫非尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79102, encryptionId=ed70e91027a, topicName=维莫非尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Sep 30 10:31:42 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663183, encodeId=7af2166318345, content=<a href='/topic/show?id=76ed183e2ef' target=_blank style='color:#2F92EE;'>#Vemurafenib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18372, encryptionId=76ed183e2ef, topicName=Vemurafenib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c625536559, createdName=ms1292405679162969, createdTime=Wed Aug 25 01:31:42 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818822, encodeId=1eb4181882215, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jan 19 08:31:42 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680734, encodeId=bfe31680e343a, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Tue Sep 14 23:31:42 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896860, encodeId=6350189686060, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 18 08:31:42 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803563, encodeId=3cc818035637e, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Wed Jun 08 11:31:42 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721040, encodeId=15921e21040a3, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Sep 17 19:31:42 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304403, encodeId=45bd1304403d2, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Mon Jun 28 09:31:42 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355030, encodeId=c105135503078, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 28 09:31:42 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1967228, encodeId=0115196e2287d, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue Jul 27 04:31:42 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045529, encodeId=d07f2045529b8, content=<a href='/topic/show?id=ed70e91027a' target=_blank style='color:#2F92EE;'>#维莫非尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79102, encryptionId=ed70e91027a, topicName=维莫非尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Sep 30 10:31:42 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663183, encodeId=7af2166318345, content=<a href='/topic/show?id=76ed183e2ef' target=_blank style='color:#2F92EE;'>#Vemurafenib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18372, encryptionId=76ed183e2ef, topicName=Vemurafenib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c625536559, createdName=ms1292405679162969, createdTime=Wed Aug 25 01:31:42 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818822, encodeId=1eb4181882215, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jan 19 08:31:42 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680734, encodeId=bfe31680e343a, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Tue Sep 14 23:31:42 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896860, encodeId=6350189686060, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 18 08:31:42 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803563, encodeId=3cc818035637e, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Wed Jun 08 11:31:42 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721040, encodeId=15921e21040a3, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Sep 17 19:31:42 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304403, encodeId=45bd1304403d2, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Mon Jun 28 09:31:42 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355030, encodeId=c105135503078, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 28 09:31:42 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
    2021-09-14 sunylz
  6. [GetPortalCommentsPageByObjectIdResponse(id=1967228, encodeId=0115196e2287d, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue Jul 27 04:31:42 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045529, encodeId=d07f2045529b8, content=<a href='/topic/show?id=ed70e91027a' target=_blank style='color:#2F92EE;'>#维莫非尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79102, encryptionId=ed70e91027a, topicName=维莫非尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Sep 30 10:31:42 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663183, encodeId=7af2166318345, content=<a href='/topic/show?id=76ed183e2ef' target=_blank style='color:#2F92EE;'>#Vemurafenib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18372, encryptionId=76ed183e2ef, topicName=Vemurafenib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c625536559, createdName=ms1292405679162969, createdTime=Wed Aug 25 01:31:42 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818822, encodeId=1eb4181882215, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jan 19 08:31:42 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680734, encodeId=bfe31680e343a, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Tue Sep 14 23:31:42 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896860, encodeId=6350189686060, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 18 08:31:42 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803563, encodeId=3cc818035637e, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Wed Jun 08 11:31:42 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721040, encodeId=15921e21040a3, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Sep 17 19:31:42 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304403, encodeId=45bd1304403d2, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Mon Jun 28 09:31:42 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355030, encodeId=c105135503078, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 28 09:31:42 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
    2021-07-18 一闲
  7. [GetPortalCommentsPageByObjectIdResponse(id=1967228, encodeId=0115196e2287d, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue Jul 27 04:31:42 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045529, encodeId=d07f2045529b8, content=<a href='/topic/show?id=ed70e91027a' target=_blank style='color:#2F92EE;'>#维莫非尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79102, encryptionId=ed70e91027a, topicName=维莫非尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Sep 30 10:31:42 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663183, encodeId=7af2166318345, content=<a href='/topic/show?id=76ed183e2ef' target=_blank style='color:#2F92EE;'>#Vemurafenib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18372, encryptionId=76ed183e2ef, topicName=Vemurafenib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c625536559, createdName=ms1292405679162969, createdTime=Wed Aug 25 01:31:42 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818822, encodeId=1eb4181882215, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jan 19 08:31:42 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680734, encodeId=bfe31680e343a, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Tue Sep 14 23:31:42 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896860, encodeId=6350189686060, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 18 08:31:42 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803563, encodeId=3cc818035637e, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Wed Jun 08 11:31:42 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721040, encodeId=15921e21040a3, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Sep 17 19:31:42 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304403, encodeId=45bd1304403d2, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Mon Jun 28 09:31:42 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355030, encodeId=c105135503078, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 28 09:31:42 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1967228, encodeId=0115196e2287d, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue Jul 27 04:31:42 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045529, encodeId=d07f2045529b8, content=<a href='/topic/show?id=ed70e91027a' target=_blank style='color:#2F92EE;'>#维莫非尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79102, encryptionId=ed70e91027a, topicName=维莫非尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Sep 30 10:31:42 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663183, encodeId=7af2166318345, content=<a href='/topic/show?id=76ed183e2ef' target=_blank style='color:#2F92EE;'>#Vemurafenib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18372, encryptionId=76ed183e2ef, topicName=Vemurafenib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c625536559, createdName=ms1292405679162969, createdTime=Wed Aug 25 01:31:42 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818822, encodeId=1eb4181882215, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jan 19 08:31:42 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680734, encodeId=bfe31680e343a, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Tue Sep 14 23:31:42 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896860, encodeId=6350189686060, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 18 08:31:42 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803563, encodeId=3cc818035637e, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Wed Jun 08 11:31:42 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721040, encodeId=15921e21040a3, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Sep 17 19:31:42 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304403, encodeId=45bd1304403d2, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Mon Jun 28 09:31:42 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355030, encodeId=c105135503078, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 28 09:31:42 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1967228, encodeId=0115196e2287d, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue Jul 27 04:31:42 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045529, encodeId=d07f2045529b8, content=<a href='/topic/show?id=ed70e91027a' target=_blank style='color:#2F92EE;'>#维莫非尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79102, encryptionId=ed70e91027a, topicName=维莫非尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Sep 30 10:31:42 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663183, encodeId=7af2166318345, content=<a href='/topic/show?id=76ed183e2ef' target=_blank style='color:#2F92EE;'>#Vemurafenib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18372, encryptionId=76ed183e2ef, topicName=Vemurafenib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c625536559, createdName=ms1292405679162969, createdTime=Wed Aug 25 01:31:42 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818822, encodeId=1eb4181882215, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jan 19 08:31:42 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680734, encodeId=bfe31680e343a, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Tue Sep 14 23:31:42 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896860, encodeId=6350189686060, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 18 08:31:42 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803563, encodeId=3cc818035637e, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Wed Jun 08 11:31:42 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721040, encodeId=15921e21040a3, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Sep 17 19:31:42 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304403, encodeId=45bd1304403d2, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Mon Jun 28 09:31:42 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355030, encodeId=c105135503078, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 28 09:31:42 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1967228, encodeId=0115196e2287d, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue Jul 27 04:31:42 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045529, encodeId=d07f2045529b8, content=<a href='/topic/show?id=ed70e91027a' target=_blank style='color:#2F92EE;'>#维莫非尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79102, encryptionId=ed70e91027a, topicName=维莫非尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Thu Sep 30 10:31:42 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663183, encodeId=7af2166318345, content=<a href='/topic/show?id=76ed183e2ef' target=_blank style='color:#2F92EE;'>#Vemurafenib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18372, encryptionId=76ed183e2ef, topicName=Vemurafenib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c625536559, createdName=ms1292405679162969, createdTime=Wed Aug 25 01:31:42 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818822, encodeId=1eb4181882215, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jan 19 08:31:42 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680734, encodeId=bfe31680e343a, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Tue Sep 14 23:31:42 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896860, encodeId=6350189686060, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 18 08:31:42 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803563, encodeId=3cc818035637e, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Wed Jun 08 11:31:42 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721040, encodeId=15921e21040a3, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Sep 17 19:31:42 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304403, encodeId=45bd1304403d2, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Mon Jun 28 09:31:42 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355030, encodeId=c105135503078, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 28 09:31:42 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
    2021-06-28 zhaojie88

相关资讯

Lancet Oncol:治疗黑色素瘤的一线药物cobimetinib+vemurafenib

如先前coBRIM研究的报道,对于未经治疗的BRAFV600突变的晚期黑色素瘤患者,联合使用cobimetinib+vemurafenib,相比安慰剂+vemurafenib,能改善无进展生存期。在这篇文章中,我们报告了最新的疗效结果,包括更长随访时间后的整体生存和安全性,并选定相关生物标志物进行研究。 在这项双盲、随机、安慰剂对照、多中心研究中,经病理证实为BRAFV600突变的IIIC、

NEJM:Vemurafenib在多种BRAF V600突变的黑色素癌的作用

BRAF V600突变发生在各种非黑色素瘤癌症中。研究人员进行了一项vemurafenib治疗BRAF V600突变阳性非黑色素瘤肿瘤组织学独立的第2阶段““basket”研究。研究人员将参加试验的患者分配在六个预先确定的癌症队列中;所有其他类型的肿瘤的患者被纳入第七个队列中。总共有122例BRAF V600突变阳性的患者进行了治疗,其中27例大肠癌患者接受vemurafenib和cetuxima

NEJM:短期内治疗复发性或难治性多毛细胞白血病,vemurafenib很有效

BRAF V600E是潜在的毛细胞白血病的遗传病变。研究人员评估了口服BRAF抑制剂vemurafenib对多毛细胞白血病患者经过嘌呤类似物治疗后复发或具有嘌呤类似物难治性的疾病患者的安全性和活性。研究人员进行了vemurafenib的两个2阶段,单组,多中心研究(960毫克的剂量,每天两次)—一个在意大利进行,一个在美国进行。该疗法给药中位时间意大利为16周,美国为18周。主要终点是完全缓解率(

2016NICE技术评估指南:cobimetinib联合vemurafenib治疗不能手术切除或转移性BRAF V600突变阳性黑色素瘤(TA414)发布

2016年10月26日,英国国家卫生与临床优化研究所(NICE)发布cobimetinib联合vemurafenib治疗不能手术切除或转移性BRAF V600突变阳性黑色素瘤(TA414)技术评估指南。全文获取:下载地址:指南下载(需要扣积分2分, 梅斯医学APP免积分下载) 

EUR J Cancer:BRAF / MEK抑制剂的使用会产生脱髓鞘性多发性神经根神经病变

BRAF / MEK抑制剂和免疫治疗剂已经被批准用于治疗转移性BRAF突变的黑色素瘤

Lancet Oncol:Vemurafenib治疗黑色素瘤安全有效

研究要点:转移性黑色素瘤的预后很差,化疗的治疗作用有限, 联合应用细胞生长抑制药物和细胞因子并不会改善患者的生存期;RAS-RAF-MEK-ERK MAPK旁路是驱动细胞转变为恶性黑色素瘤细胞的主要动力,因此患者可从BRAF抑制治疗中得到的获益;在黑色素瘤患者中,无论其存在的是最常见的BRAFV600E突变还是最少见的BRAFV600K突变,应用vemurafenib针对BRAF进行抑制都能显

Baidu
map
Baidu
map
Baidu
map